Dr. Rieger is an Associate Professor at the University of Miami and is affiliated with the Sylvester Comprehensive Cancer Center at the Miller School of Medicine. Her research focuses on elucidating the mechanisms underlying peripheral neuropathy with specific focus on identifying key pathways implicated in chemotherapy-induced and diabetic peripheral neuropathy. Her group identified a common pathway that is activated in the epidermis following paclitaxel and glucose treatment. This pathway initiates the degeneration of sensory nerve endings in the skin by inducing the formation of skin-specific reactive oxygen species, which, in turn, leads to the upregulation of the extracellular matrix-degrading enzyme MMP-13. Activated MMP-13 promotes collagen degradation and disrupts the interactions between sensory nerve endings and the extracellular matrix, ultimately leading to the degeneration of peripheral nerve endings. Dr. Rieger is presently developing drugs that could potentially prevent or reverse paclitaxel-induced and diabetic peripheral neuropathy.
Dr. Rieger is an Associate Professor at the University of Miami and is affiliated with the Sylvester Comprehensive Cancer Center at the Miller School of Medicine. Her research focuses on elucidating the mechanisms underlying peripheral neuropathy with specific focus on identifying key pathways implicated in chemotherapy-induced and diabetic peripheral neuropathy. Her group identified a common pathway that is activated in the epidermis following paclitaxel and glucose treatment. This pathway initiates the degeneration of sensory nerve endings in the skin by inducing the formation of skin-specific reactive oxygen species, which, in turn, leads to the upregulation of the extracellular matrix-degrading enzyme MMP-13. Activated MMP-13 promotes collagen degradation and disrupts the interactions between sensory nerve endings and the extracellular matrix, ultimately leading to the degeneration of peripheral nerve endings. Dr. Rieger is presently developing drugs that could potentially prevent or reverse paclitaxel-induced and diabetic peripheral neuropathy.